Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes
Richardson PG (1), Harvey RD (2), Laubach JP (1), Moreau P (3), Lonial S (2), San-Miguel JF (4).
(1a) Dana-Farber Cancer Institute , Harvard Medical School , Boston , MA , USA.
(2b) Winship Cancer Institute , Emory University , Atlanta , GA , USA.
(3c) Hematology Department , University Hospital , Nantes , France.
(4d) CIMA, IDISNA , Clínica Universidad de Navarra , Pamplona , Spain.
Recently, outcomes for patients with multiple myeloma have improved dramatically due to improved and innovative therapies. However, most patients will either relapse or become refractory to current therapy.
Thus, a significant unmet need remains for novel agents to treat this patient population. Panobinostat, a potent pan-deacetylase inhibitor with a unique mechanism of action targeting both epigenetic regulation of gene expression and protein metabolism, has preclinical synergy with a number of agents, including the proteasome inhibitor bortezomib.
In a phase 3 trial of panobinostat with bortezomib and dexamethasone, addition of panobinostat significantly prolonged the median progression-free survival of patients with relapsed or relapsed and refractory multiple myeloma.
This review focuses on clinical development of panobinostat, with particular emphasis on pharmacokinetics and adverse event management.
CITATION Expert Rev Clin Pharmacol. 2016;9(1):35-48. doi: 10.1586/17512433.2016.1096773. Epub 2015 Oct 26.